| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/17/2004 | US20040115690 Method of detecting inflammatory lung disorders |
| 06/17/2004 | US20040115666 Method for identifying compounds modulating reverse cholesterol transport |
| 06/17/2004 | US20040115656 Androgen receptor down-regulatory-associated proteins(ARDAPs) for use in reduction of transactivation activity of androgen receptors and treatment of tumors; gene expression inhibition and anticarcinogenic agents |
| 06/17/2004 | US20040115587 Methods and systems for enabling and stabilizing tooth movement |
| 06/17/2004 | US20040115283 Administering parenterally a therapeutically effective amount of one or more arsenic compounds |
| 06/17/2004 | US20040115276 Liquid pharmaceutical for oral delivery |
| 06/17/2004 | US20040115243 Compositions for oral delivery of nutrients and pharmaceuticals |
| 06/17/2004 | US20040115220 Vaccine |
| 06/17/2004 | US20040115208 forming a colloidal metal-protein complex by contacting colloidal metal with a tumor cell in an aqueous solution |
| 06/17/2004 | US20040115202 monospecific antibody which specifically binds an epitope of a mammalian DPPIV (dipeptidyl peptidase IV, also known as CD26). |
| 06/17/2004 | US20040115197 Remedies for infant chronic arthritis-relating diseases |
| 06/17/2004 | US20040115185 Placental alkaline phosphatase to control diabetes |
| 06/17/2004 | US20040115175 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells |
| 06/17/2004 | US20040115167 applied to the skin of a living animal, causing the microprojections to pierce the stratum corneum and to deliver an effective dose of the biologically active agent and vasoconstrictor to the animal. |
| 06/17/2004 | US20040115127 Simultaneous selective binding and activating |
| 06/17/2004 | CA2508301A1 Low viscosity liquid dosage forms |
| 06/17/2004 | CA2507748A1 Pharmaceutical formulations comprising .beta.-2 adrenoreceptor agonists and xanthines |
| 06/17/2004 | CA2507036A1 Materials and methods for treating ocular-related disorders |
| 06/17/2004 | CA2507011A1 Phosphoantigens for regulating an immune response |
| 06/17/2004 | CA2506630A1 Heart failure gene determination and therapeutic screening |
| 06/17/2004 | CA2504801A1 Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| 06/17/2004 | CA2503973A1 Material compositions and related systems and methods for treating cardiac conditions |
| 06/16/2004 | EP1428880A1 Kidney-specific urate transporter and gene thereof |
| 06/16/2004 | EP1428824A1 Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 06/16/2004 | EP1428533A2 Use of thiazolidine- or pyrrolidine-derivatives of aminoacids as antihyperglycemic agents |
| 06/16/2004 | EP1428532A1 Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427855A2 Method and reagents for identifying gene targets for treating breast cancer |
| 06/16/2004 | EP1427846A2 Method of identifying glycosyl transferase binding compounds |
| 06/16/2004 | EP1427844A1 New assay for inhibitors of translocases |
| 06/16/2004 | EP1427842A2 Mid 9002, a human sulfatase family member and uses therefor |
| 06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
| 06/16/2004 | EP1427838A1 Plant enzymes for bioconversion |
| 06/16/2004 | EP1427837A2 Modular transfection systems |
| 06/16/2004 | EP1427831A1 Yeast membrane protein expression system and its application in drug screening |
| 06/16/2004 | EP1427830A2 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY |
| 06/16/2004 | EP1427825A2 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 06/16/2004 | EP1427813A2 Method for dendritic cells-based immunotherapy of tumors using combination therapy |
| 06/16/2004 | EP1427754A1 Nucleic acid and polypeptide linked to breast cancer and uses therefor |
| 06/16/2004 | EP1427724A1 Novel use of substituted aminomethyl chromans |
| 06/16/2004 | EP1427718A1 Benzothiepine ileal bile acid transport inhibotors |
| 06/16/2004 | EP1427713A1 Benzothiazepine derivatives for the treatment of hyperlipidemia |
| 06/16/2004 | EP1427712A2 Dye-azide compounds for dual phototherapy |
| 06/16/2004 | EP1427450A2 Inhibition of rna function by delivery of inhibitors to animal cells |
| 06/16/2004 | EP1427447A1 Improved therapeutic protocols |
| 06/16/2004 | EP1427427A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 06/16/2004 | EP1427422A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases |
| 06/16/2004 | EP1427420A1 Use of 4-pyridylmethylphthalazines for cancer treatment |
| 06/16/2004 | EP1427411A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo 3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 06/16/2004 | EP1427410A1 Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration |
| 06/16/2004 | EP1427409A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |
| 06/16/2004 | EP1427403A2 Valproic acid and derivatives for the combination treatment of human cancers, tumor metastasis and minimal residual disease |
| 06/16/2004 | EP1427401A2 Method for reducing hypertension and heart failure |
| 06/16/2004 | EP1427399A2 Retinoid receptor pan-antagonists for stimulating chondrogenesis |
| 06/16/2004 | EP1427391A1 Vascular occlusion solid-phase agent with immobilised platelet binding agent |
| 06/16/2004 | EP1427390A1 Drug delivery system |
| 06/16/2004 | EP1427383A1 Compositions and methods relating to prevention of chemotherapy-induced alopecia |
| 06/16/2004 | EP1427379A2 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| 06/16/2004 | EP1427326A2 Combination therapy for the treatment of cancer |
| 06/16/2004 | EP1355660A4 Therapeutic modulation of the tumor inflammatory response |
| 06/16/2004 | EP1326622A4 Compositions and methods for treatment of multiple myeloma |
| 06/16/2004 | EP1221950B1 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
| 06/16/2004 | EP1218401B1 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use |
| 06/16/2004 | EP1214074B1 Dioxolane nucleoside analogs for the treatment or prevention of viral infection |
| 06/16/2004 | EP1194132B1 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 06/16/2004 | EP1187539A4 Method and composition for masking mineral taste |
| 06/16/2004 | EP1121106B1 Treatment of indigestion |
| 06/16/2004 | EP1100433B1 Finely dispersed emulsifier-free systems of the oil-in-water and water-in-oil type, containing boron nitride |
| 06/16/2004 | EP1030670B1 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents |
| 06/16/2004 | EP1027053B1 Method of preventing nephrotoxicity caused by cyclosporins or tacrolimus |
| 06/16/2004 | EP1014961B1 Treatment of migraine headache using metoclopramide and an nsaid |
| 06/16/2004 | EP0923399B1 Kit of parts comprising three vials for embolizing vascular sites with an embolizing composition comprising dimethylsulfoxide |
| 06/16/2004 | EP0906102B1 A process for regulating vagal tone |
| 06/16/2004 | EP0881908B1 Use of fibroblast growth factors to stimulate bone growth |
| 06/16/2004 | EP0787003B1 Animal model system for the testing of drug candidates for the treatment of leukemia or hiv |
| 06/16/2004 | CN1505638A Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| 06/16/2004 | CN1505636A Pharmaceutically active uridine esters |
| 06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
| 06/16/2004 | CN1505527A Combination therapy using anti-angiogenic agents and tnfa |
| 06/16/2004 | CN1505526A Compositions and methods for wt1 specific immunotherapy |
| 06/16/2004 | CN1505522A Stimulation of thymus for vaccination development |
| 06/16/2004 | CN1505521A Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof |
| 06/16/2004 | CN1505514A Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| 06/16/2004 | CN1505511A Use of pyridoindolone derivatives for preparing medicines |
| 06/16/2004 | CN1505510A Medicine combinations using pyridoindolone derivatives and anticancer agent as base |
| 06/16/2004 | CN1505502A Fibrate-statin combinations with reduced fed-fasted effects |
| 06/16/2004 | CN1505498A Composition for hair and/or scalp |
| 06/16/2004 | CN1504475A Polynucleotide for identifying polypeptide OT10 and coding OT10 of tumor cell and uses thereof |
| 06/16/2004 | CN1504185A 药物组合物 The pharmaceutical composition of |
| 06/16/2004 | CN1153567C Scale production method of forming microparticles |
| 06/15/2004 | US6750348 Protective effects against infection by hiv through binding to chemokine receptors, including cxcr4 and ccr5;n-(2-pyridinylmethyl)-n'-(2-(phenylureido)ethyl)-n'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine |
| 06/15/2004 | US6750323 Platelet activation protein |
| 06/15/2004 | US6750253 Aminobenzophenones as inhibitors of il-1β and tnf-α |
| 06/15/2004 | US6750242 Positive modulators of nicotinic receptor agonists |
| 06/15/2004 | US6750239 Useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 06/15/2004 | US6750238 Aralkyl ester soft drugs |
| 06/15/2004 | US6750235 Pramipexole as a treatment for cocaine craving |
| 06/15/2004 | US6750221 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 06/15/2004 | US6750216 Kappa agonist compounds and pharmaceutical formulations thereof |
| 06/15/2004 | US6750215 Antitumor agents; anticancer agents |